Asthma—a chronic inflammatory disease impacting over 350 million people worldwide—limits lives with symptoms like wheezing, shortness of breath, and chest tightness. Whether it’s allergic, exercise-induced, or nocturnal asthma, each type requires a unique approach for effective management.
Fortunately, the biotech sector is bringing incredible advancements in managing asthma. From biologic therapies like Dupilumab and Tezepelumab to personalized medicine and digital inhalers with adherence monitoring, the future is brighter than ever.